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Chronic rhinosinusitis (CRS) is a heterogeneous disease characterized by local inﬂammation of the upper
airways and sinuses which persists for at least 12 weeks. CRS can be divided into two phenotypes
dependent on the presence of nasal polyps (NPs); CRS with NPs (CRSwNP) and CRS without NPs
(CRSsNP). Immunological patterns in the two diseases are known to be different. Inﬂammation in
CRSsNP is rarely investigated and limited studies show that CRSsNP is characterized by type 1 inﬂam-
mation. Inﬂammation in CRSwNP is well investigated and CRSwNP in Western countries shows type 2
inﬂammation and eosinophilia in NPs. In contrast, mixed inﬂammatory patterns are found in CRSwNP in
Asia and the ratio of eosinophilic NPs and non-eosinophilic NPs is almost 50:50 in these countries.
Inﬂammation in eosinophilic NPs is mainly controlled by type 2 cytokines, IL-5 and IL-13, which can be
produced from several immune cells including Th2 cells, mast cells and group 2 innate lymphoid cells
(ILC2s) that are all elevated in eosinophilic NPs. IL-5 strongly induces eosinophilia. IL-13 activates
macrophages, B cells and epithelial cells to induce recruitment of eosinophils and Th2 cells, IgE mediated
reactions and remodeling. Epithelial derived cytokines, TSLP, IL-33 and IL-1 can directly and indirectly
control type 2 cytokine production from these cells in eosinophilic NPs. Recent clinical trials showed the
beneﬁcial effect on eosinophilic NPs and/or asthma by monoclonal antibodies against IL-5, IL-4Ra, IgE
and TSLP suggesting that they can be therapeutic targets for eosinophilic CRSwNP.
Copyright © 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V. All rights reserved.Introduction
Chronic rhinosinusitis (CRS) is a heterogeneous disease char-
acterized by local inﬂammation of the upper airways and sinuses
that persists for at least 12 weeks. It is a signiﬁcant cause of
morbidity in adults across the world, affecting over 10 million
Americans.1e4 CRS is frequently divided into two groups based on
the presence or absence of nasal polyps (NPs): CRS with NPs
(CRSwNP) and CRS without NPs (CRSsNP). Inﬂammatory patterns
in the two diseases are known to be different. Initial studiesof Medicine, Northwestern
on, Room M305, Chicago, IL
ety of Allergology.
rgology. Production and hosting by Elsindicated that CRSsNP is characterized by type 1 inﬂammation and
CRSwNP by type 2 inﬂammation.4e7 However, recent evidence
suggests that this theory may not ﬁt in Asia where mixed inﬂam-
matory patterns can frequently be found in Asian patients in
contrast to those inWestern countries. This review article will focus
on the pathogenic role of immune cells in CRS and will clarify the
current knowledge of inﬂammatory patterns in CRSsNP and
CRSwNP in the Western and Asian populations.
CRS is also known to be characterized by tissue remodeling.
However, the pattern of remodeling between CRSsNP and CRSwNP is
different.8e11 Importantly, this variation is controlled by distinct in-
ﬂammatory patterns, known to bedifferent in the twodiseases. Since
these patterns are controlled by immune signaling,wewill introduce
remodeling as an example of differences between CRSsNP and
CRSwNP that is controlled by immune signaling and then introduce
the inﬂammatory patterns in CRS in the following sections.evier B.V. All rights reserved.
A. Kato / Allergology International 64 (2015) 121e130122Remodeling
Tissue remodeling in CRS includes changes to the tissue structure
and the deposition of extracellular matrix (ECM).12,13 Several factors
that have been implicated in remodeling including matrix metal-
loproteinase (MMP) and TGF-b are well invested molecules in CRS.
MMPs are a family of zinc-dependent proteolytic enzymes that
degrade various components of ECM and mediate remodeling in
both physiological and pathological processes.14 Several groups have
investigated a subset of MMPs in CRS and shown that MMP-7 and
MMP-9 were elevated in both CRSsNP and CRSwNP.9,10,15 This sug-
gests that MMP-7 andMMP-9might be remodeling factors common
to both forms of CRS. TGF-b mediates anti-inﬂammatory effects by
acting onmany types of immune cells.16 TGF-b also affects ﬁbrosis by
increasing deposition of ECM such as collagen, ﬁbronectin and pro-
teoglycan.17 TGF-b has three isoforms, TGF-b1, TGF-b2 and TGF-b3.
Van Bruaene et al. reported in the Belgium population that TGF-b1,
TGF-b2, and collagenwere elevated in CRSsNP.8 The same group also
investigated the presence of TGF-b in the Chinese population. Li et al.
reported that TGF-b1 and collagen were elevated in CRSsNP.9 In
contrast, Shi et al. found in the Chinese population that TGF-b1 was
reduced but TGF-b2 and collagen were elevated in CRSsNP.10 Addi-
tionally, Sejima et al. reported that TGF-bwas elevated in CRSsNP in
the Japanese population although they did not state the isoform.18
Although there is some discrepancy, these studies suggest that
TGF-b and collagen are elevated in CRSsNP across theworld andmay
contribute to the remodeling process in this form of the disease.
As mentioned above, the pattern of remodeling in CRSwNP is
known to be different compared to CRSsNP. Indeed, collagen was
reduced in CRSwNP and TGF-b was either reduced or no difference
compared to control subjects.8e11 In contrast to CRSsNP, the fact that
ﬁbrin deposition in the submucosa is especially high in NPs might
represent a key event in the tissue remodeling process during
CRSwNP.11,19 Takabayashi et al. recently reported that cross-linked
ﬁbrin was elevated and tissue plasminogen activator (t-PA) was
reduced in NPs.11 The t-PA converts plasminogen to plasmin which
promotes ﬁbrin degradation.11,20 Importantly, type 2 cytokines, IL-4
and IL-13 which are elevated in NPs, reduced the expression of t-
PA in epithelial cells.11 In a separate study, Takabayashi et al. reported
that factor XIII-A (FXIIIA) was signiﬁcantly elevated in NPs and it was
produced byM2macrophages (also known as alternatively activated
macrophages).19 FXIIIA is a coagulation factor that can induce ﬁbrin
deposition by cross-linkingﬁbrin and via the antiﬁbrinolytic effect by
mediating the binding of a2-plasmin inhibitor to ﬁbrin.19,21,22 This
data suggests that overexpression of FXIIIA and reduction of t-PA
may facilitate the excessive deposition of ﬁbrin in NPs via induction
of ﬁbrin cross-linking and the inhibition of ﬁbrinolysis (Fig. 1). Very
importantly, these factors are tightly controlled by the type 2 in-
ﬂammatory milieu. Therefore they may not be a good ﬁt to describe
the mechanism of remodeling in non-eosinophilic Asian NPs (see
following sections), which requires further study.
As we mention above, CRSsNP and CRSwNP are controlled by
distinct inﬂammatory signals from various immune cells. Indeed,
remodeling in CRSsNP might be controlled by TGF-b signaling. In
contrast, remodeling in CRSwNP is regulated by type 2 inﬂamma-
tion. In addition, CRSwNP can be further divided into two pheno-
types based on inﬂammatory patterns. Starting in the next section,
wewill describe the inﬂammatory patterns in CRSsNP and CRSwNP
separately and also focus on the difference between the two types
of CRSwNP; eosinophilic and non-eosinophilic.
Inﬂammatory patterns in CRSsNP
The mechanism of inﬂammation in CRSsNP is poorly under-
stood. Van Zele et al. initially discovered that the type 1 cytokineIFN-g was signiﬁcantly elevated in CRSsNP in Belgium.6 Several
groups conﬁrmed the elevation of IFN-g in CRSsNP in Belgium,
China and Korea.23e25 In contrast, other groups could not ﬁnd
elevation of IFN-g in CRSsNP in Japanese, Chinese and American
populations.7,18,26 Another CRSsNP dependent cytokine could be
TGF-b. Van Bruaene et al. discovered that TGF-bwas predominantly
elevated in CRSsNP and several groups conﬁrmed the elevation of
TGF-b in CRSsNP in Asia although there is some discrepancy (see
remodeling section).8e10,18 Since CRSsNP is a heterogeneous dis-
ease and is diagnosed by the phenotypic absence of NPs, the sample
population may strongly affect the result. Future studies may
require sub-classiﬁcation of CRSsNP and investigation of the in-
ﬂammatory patterns in each group.
Eosinophilic and non-eosinophilic CRSwNP
CRSwNP is well known to be characterized by type 2 inﬂam-
mation and eosinophilia compared to CRSsNP or control sinus
mucosa. However, the inﬂammation in CRSwNP varies based on
race and regional differences. Several studies have indicated that
70e90% of CRSwNP in Europe and the United States showed
eosinophilia in NPs.4,6,27e32 We also have found intense inﬁltration
of eosinophils in NPs. Our data showed that eosinþ and EG2þ eo-
sinophils were highly accumulated in the lamina propria as well as
in the epithelium of NPs (Fig. 2A, B). However, this does not hold
true in East Asia including China, Korea and Japan. Zhang et al.
reported that the levels of eosinophilia in NPs were signiﬁcantly
weaker in south China than in Belgium.31 Cao et al. reported that
more than 50% of CRSwNP presented non-eosinophilic inﬂamma-
tion in China.24 Eosinophilic NPs have also been found in less than
50% of patients in Japan and Korea.33e35 Although these studies
suggest that eosinophilic NPs in East Asia are less frequent, some
studies in China showed a higher frequency of eosinophilia in NPs.
Indeed, Wen et al. used a larger cohort of patients with CRSwNP in
China and found that 76.5% had eosinophilia in NPs.36 The
discrepancy in these results could be explained by the fact that
every researcher used a different estimation system to determine
the eosinophilia. Indeed, Cao et al., Wen et al. and Kim et al.
randomly collected 10 high power ﬁeld (HPF) images and deter-
mined eosinophilia.24,36,37 However, Cao et al. used 10% eosinophils
in HPF, Wen et al. used 8 eosinophils/HPF and Kim et al. used 5
eosinophils/HPF as cutoff values.24,36,37 In another case, Ikeda et al.
and Yoshimura et al. collected three HPFs containing the greatest
degree of cellular inﬁltration and determined the eosinophilia by
cutoff values of 100 eosinophils/HPF and 15% eosinophils in HPF,
respectively.33,35 These conﬂicting results highlight the need for
internationally recognized guidelines for determination of eosino-
philic and non-eosinophilic NPs in CRSwNP. On balance, eosino-
philic NPs are a common phenotype in Europe and the United
States, however in East Asia, eosinophilia is less frequent and about
half of CRSwNP is characterized by non-eosinophilic NPs. Recent
studies indicate that the prevalence of eosinophilic NPs is
increasing in Asia. Kim et al. evaluated eosinophilia in NPs obtained
from 1993e1994 and 2010e2011 and found that the prevalence of
eosinophilic NPs increased from 24.0% to 50.9% in Korea.37 Kato-
tomichelakis et al. evaluated NPs at two time points, 1999 and 2011,
in Thailand, and found that the average number of eosinophils/HPF
changed to 35 from 5.38 It is possible that eosinophilic NPs may
continue to increase in Asia in the future.
In contrast to eosinophilic inﬂammation, inﬂammatory patterns
in non-eosinophilic NPs are poorly understood. Non-eosinophilic
NPs can be divided into several phenotypes and neutrophilia is
the best characterized phenotype in non-eosinophilic NPs. In China,
Wen et al. showed that 46.0% of NPs had neutrophilia and 35.8% had
a mixed phenotype with eosinophilia.36 Ikeda et al. showed 20% of
Fig. 1. Potential mechanism for ampliﬁcation of type 2 inﬂammation in eosinophilic CRSwNP. Several factors including fungi, proteases, S. aureus, bacteria, viruses and allergens can
activate nasal epithelial cells to induce the production of epithelial derived cytokines TSLP, IL-33 and IL-1. Epithelial derived cytokines activate three types of immune cells in NPs.
TSLP stimulates mDCs to induce naive CD4þ T cell differentiation into Th2 cells which then induce adaptive type 2 inﬂammation. TSLP and IL-33 stimulate ILC2s to induce the
production of type 2 cytokines (innate type 2 inﬂammation). Mast cells are accumulated in the epithelium and are also present in the mucosal area in NPs. TSLP, IL-33 and IL-1
stimulate epithelial and mucosal mast cells to produce IL-5 and IL-13 (innate type 2 inﬂammation). Ag/IgE/IgER complexes on mast cells induce degranulation and thereafter
mast cells produce IL-5 and IL-13 (adaptive type 2 inﬂammation). Production of PGD2 and LTC4 from mast cells also stimulates ILC2s. IL-5 promotes eosinophilia and eosinophils
produce CCL23 to recruit macrophages and mDC. IL-4/13 activates macrophages, B cells and epithelial cells to induce eosinophil and Th2 cell recruitment, remodeling and IgE
mediated reactions. M2 macrophages produce eotaxins and CCL18 to recruit eosinophils, mDCs and Th2 cells.
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of Germany, Polzehl et al. showed that neutrophils were detected in
early stage NPs but they were not elevated compared to control
nasal mucosa.30 Van Zele et al. showed that neutrophils were
signiﬁcantly elevated in NPs in Belgium, although the degree of
neutrophilia was signiﬁcantly weaker than eosinophilia in those
NPs.6 We also detected neutrophils and a subset of NPs showed
elevation of neutrophils mixed with eosinophilia in the US (Fig. 2C,
unpublished observation). This evidence indicates that neutrophilic
CRSwNP is more commonly found in Asia. In contrast, neutrophil
inﬁltration can be found in Europe and the US and it is generally
mixed with eosinophilia. However, the degree of neutrophilia is
weaker than eosinophilia.
Inﬂammatory patterns in eosinophilic CRSwNP
Since CRSwNP is characterized by eosinophilia in western coun-
tries, many researchers have investigated the role of eosinophil
activation and survival factors in NPs. Hamilos et al. and others
initially discovered that IL-5 was elevated in allergic NPs.39 Simon
et al. and others conﬁrmed the elevation of IL-5 in NPs and identiﬁed
that IL-5 was a major eosinophil survival factor in NPs.40 After that,
many investigators conﬁrmed the elevation and importance of IL-5 in
eosinophilic NPs across the world.6,7,18,23e25,29,31 Since IL-5 is a key
factor of eosinophilia, Gevaert et al. performed clinical trials of anti-
IL-5 in severe cases of NPs. Both mepolizumab and reslizumab,
which are humanized anti-human IL-5monoclonal antibodies, result
in a signiﬁcant reduction ofNP size in50e60%patients and IL-5 levelsin nasal secretion can be predictive of response to anti-IL-5
therapy.41,42
In addition to activation and survival, eosinophil recruitment
into tissue should be another key event to induce eosinophilia.
Chemokines are a large group of proteins that participate in
recruitment of inﬂammatory cells into tissue sites by binding G
protein-coupled receptors on their target cells. Among them,
chemokine receptor CCR3 is predominantly expressed on eosin-
ophils and 5 chemokines, MCP-4 (CCL13), RANTES (CCL5), eotaxin-
1 (CCL11), eotaxin-2 (CCL24) and eotaxin-3 (CCL26), are well
known to recruit eosinophils via CCR3. Several researchers
investigated these chemokines in eosinophilic CRSwNP. The
importance of RANTES in NPs is still not clear and several groups
showed that RANTES was not elevated in eosinophilic NPs.43
Although MCP-4 is a potent chemoattractant, the presence of
MCP-4 in eosinophilic NPs is not well studied and only a few
studies show the elevation of MCP-4 in NPs.44,45 In contrast, many
researchers reported the importance of eotaxins in NPs. Ponath
et al. cloned human eotaxin-1 as an eosinophil chemoattractant
factor and found it in eosinophilic NPs.46 Many researchers then
investigated individual eotaxins in eosinophilic NPs and found
that they were elevated. Importantly, Olze et al. Yao et al. and
Takabayashi et al. investigated three eotaxins and found that
eostaxin-1, -2 and -3 were all elevated in eosinophilic NPs.47e49
Furthermore, several investigators found a correlation between
eotaxins and tissue eosinophilia in CRSwNP.47 These results indi-
cate that eotaxins are key chemotactic factors for eosinophils in
eosinophilic NPs.
Fig. 2. Increased presence of immune cells in NPs. Representative H&E staining in NPs is shown in A. Representative immunostainings were performed with anti-ECP mAb (EG2) for
eosinophils (B), anti-neutrophil elastase (NE) mAb for neutrophils (C), anti-tryptase mAb for mast cells (D), anti-CD163 mAb for M2 macrophages (E), anti-CD1c mAb for mDC1s (F),
anti-CD3 mAb for T cells (G) and anti-CD20 mAb for B cells (H). Immunoﬂuorescence assay was performed with anti-CD3 mAb (red ﬂuorescence), anti-CD20 mAb (green ﬂuo-
rescence) and anti-CD138 mAb (orange ﬂuorescence) for plasma cells (I), Nuclei were counterstained with 406-diamidino-2- phenylindole (DAPI; blue ﬂuorescence).
Magniﬁcation;200.
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Type 2 cytokines including IL-4, IL-5 and IL-13 are believed to
control the inﬂammation in eosinophilic CRSwNP. As described
above, IL-5 is a key activation and survival factor for eosinophils in
NPs. In contrast, IL-4 and IL-13 are key factors that control mucus
production in epithelial cells and IgE responses in B cells and
plasma cells (Fig. 1). IL-4 and IL-13 also signiﬁcantly contribute to
several key inﬂammatory events in NPs including the activation of
macrophages and remodeling. Very recently, a Phase 2a proof-of-
concept study of dupilumab, which is a fully human monoclonal
antibody against the a-subunit of the IL-4 receptor that blocks both
IL-4 and IL-13 signaling, showed improvement of NP score as well
as patient-reported symptom scores in moderate-to-severe
CRSwNP (http://newsroom.regeneron.com/releasedetail.cfm?
ReleaseID¼873630). This reinforces the importance of type 2
inﬂammation in the pathogenesis of eosinophilic CRSwNP.
Type 2 cytokines, IL-4, IL-5 and IL-13, can be produced from
several immune cells including Th2 cells, mast cells and group 2
innate lymphoid cells (ILC2s). Type 2 cytokines can be induced by
both adaptive and innate signaling in these cell types. Recent evi-
dence suggests that newly identiﬁed epithelial-derived cytokines,IL-25, IL-33 and thymic stromal lymphopoietin (TSLP), help to
shape the local activation of type 2 immunity and exaggerated
expression of these cytokines induces type 2 inﬂammatory diseases
including atopic dermatitis and bronchial asthma.50e53 These
epithelial-derived cytokines can have effects on both innate and
adaptive type 2 immunity. Therefore many investigators have
started to look at these epithelial cytokines in CRS.
IL-25 and IL-33 mainly contribute to innate type 2 inﬂamma-
tory responses.54,55 IL-25 is a member of the IL-17 cytokine family.
Unlike other IL-17 family cytokines, IL-25 promotes type 2
inﬂammation including eosinophilia even in Rag2 deﬁcient
mice.55 IL-25R is expressed on memory Th2 cells, basophils and
ILC2s and IL-25 enhances type 2 cytokine production in these
cells.56 In the case of CRS, only a few groups have investigated the
presence of IL-25. Lam et al. reported that IL-25 mRNA was
signiﬁcantly elevated in ethmoid sinuses of CRSwNP compared to
controls and CRSsNP.57 In contrast, Miljkovic et al. reported that IL-
25 mRNA was signiﬁcantly decreased in NPs compared to ethmoid
sinuses of controls and CRSsNP.58 Our data showed that expression
of mRNA for IL-25 was very low in sinuses and the level of IL-25
mRNA was similar between NPs and control sinus tissues (un-
published observations). In addition, no one has yet shown the
presence of IL-25 protein in CRS. On balance, IL-25 may not be a
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study will be required to investigate the presence of IL-25 protein
in eosinophilic NPs.
IL-33 is the latest member of the IL-1 cytokine family that in-
duces type 2 inﬂammation.59 The production of IL-33 is known to
be controlled by innate immune signaling including via P2 puri-
nergic receptors.60 IL-33 signals through a heterodimeric receptor
complex consisting of IL-1RL1 (ST2) and IL-1RAcP. IL-33R is
expressed onmemory Th2 cells, basophils, mast cells, NKT cells and
ILC2s.56 IL-33 induces type 2 inﬂammation in Rag deﬁcient mice
suggesting that IL-33 mainly contributes to innate type 2 inﬂam-
mation.54 In the case of CRS, several groups reported the presence
of IL-33 in CRS. Shaw et al. Lam et al. and Miljkovic et al. reported
that IL-33 mRNAwas highly expressed in nasal mucosa but was not
elevated in NPs or other inﬂamed areas of the sinuses in
CRSwNP.57,58,61 Baba et al. also found that the concentration of IL-33
protein was not signiﬁcantly different between eosinophilic NPs
and control sinus tissue although it was highly detected.62 These
results indicate that IL-33 may contribute to the inﬂammation in
CRS but is not elevated in CRSwNP.
TSLP is an IL-7 like cytokine that induces type 2 inﬂammation.
Several animal studies indicated that TSLP may contribute to both
innate and adaptive type 2 inﬂammation.63,64 The production of
TSLP is known to be controlled by both innate and adaptive
immune signaling including via activation of toll like receptors
and cytokine receptors.51,52,65,66 In contrast to IL-25 and IL-33,
TSLP was reproducibly reported to have a pathogenic role in
CRSwNP. Indeed, several groups reported that TSLP mRNA was
signiﬁcantly elevated in eosinophilic NPs in the US, Canada,
China, Japan and Italy.7,67e71 Although it is notably difﬁcult to
detect TSLP protein in clinical samples by commercially available
detection systems, Nagarkar et al. and Allakhverdi et al. found
that TSLP activity was signiﬁcantly elevated in NPs compared to
control sinus tissue.7,67 This indicates that TSLP protein is
elevated in NPs. Interestingly, Nagarkar et al. discovered cleavage
products of TSLP when TSLP protein was incubated with NP tissue
extracts.7 More importantly, they also found that the cleaved
product might have higher activity than full-length TSLP.7 These
results suggest that regulation of induction and posttranslational
modiﬁcations in tissue control local TSLP-mediated type 2
inﬂammation. Very importantly, a recent clinical trial showed
that AMG 157 which is a fully human anti-TSLP monoclonal
antibody reduced allergen-induced early and late asthmatic re-
sponses in patients with mild allergic asthma.72 This indicates
that TSLP is a key factor and an important therapeutic target in
asthma. Since TSLP may also control type 2 inﬂammation in
eosinophilic NPs, anti-TSLP may become a therapeutic agent for
CRSwNP in the future.
Based on the literature, TSLP may be a key controller of type 2
immunity in eosinophilic NPs. IL-33 may also be involved in the
inﬂammation although it is not elevated in CRS. Starting in the next
section, wewill describe the presence of type 2 cytokine producing
cells and the potential role of epithelial-derived cytokines on type 2
inﬂammation in eosinophilic NPs.
T cells and dendritic cells
T cells are known to be elevated in eosinophilic NPs and T cell
accumulation can be found in both mucosal and epithelial areas of
NPs (Fig. 2G). Th2 cells are known as the primary source of type 2
cytokines. Recently, two separate groups have provided an in-depth
analysis of Th cell subsets found in NPs. Derycke et al. reported that
NPs were characterized by mixed T helper cells and only Th2 cells
were signiﬁcantly elevated in NPs in Belgium.73 Shi et al. reported
that increased Th2 cells were found only in eosinophilic NPsalthough Th1 cells and Th17 cells were elevated in both eosino-
philic and non-eosinophilic NPs in China.74 These results suggest
that Th2 cells are highly elevated in eosinophilic CRSwNP across the
world.
Although TSLP directly promoted Th2 differentiation from naïve
T cells in the absence of antigen presenting cells (APC) in mice,75,76
TSLP dependent-Th2 differentiation required APC in humans.77,78
TSLP-R was not expressed on naïve T cells and TSLP did not
directly induce Th2 cytokine production in naïve T cells in humans,
although expression of TSLP-R was weakly induced by TCR-
dependent activation on naïve T cells and by allergen plus TSLP
on a subset of Th2 cells in atopic subjects.79e81 Therefore TSLP
dependent-Th2 differentiation is believed to be controlled by
dendritic cells (DCs) in humans.
Dendritic cells are known to be important in skewing Th re-
sponses in the mucosa. Human DCs can be divided into two major
subsets, myeloid DCs (mDCs) and plasmacytoid DCs (pDCs).82
Myeloid DCs act as strong antigen presenting cells and one of
their key functions is to control polarization of T helper cells. In
contrast, pDCs are less effective at antigen presentation than mDCs
but strongly promote antiviral immunity. Recently, three groups
identiﬁed DC subsets in NPs and found that mDCs were signiﬁ-
cantly elevated in NPs in the US, Belgium and China.74,83,84 Myeloid
DCs can be classiﬁed into two subsets in humans, mDC1 and mDC2,
which can be differentiated by cell surface expression of CD1c and
CD141, respectively. Poposki et al. and Pezato et al. further differ-
entiated mDC phenotypes and found that both mDC1s and mDC2s
were signiﬁcantly elevated in NPs although mDC2s were a minor
population of mDCs in NPs.83,84 Importantly, Yerkovich et al. re-
ported that mDC2s were signiﬁcantly elevated in patients with
atopic asthma, and found that mDC2s strongly induced a Th2-
polarized response although the mechanisms were not clear.85
This suggests that the elevation of mDC2s in NPs may contribute
to the local Th2-polarized environment. However, the mechanism
needs further investigation.
In contrast to mDC2, the mechanisms of mDC1-related Th2
polarization are partially identiﬁed. Shi et al. evaluated DC subsets
fromNPs of eosinophilic and non-eosinophilic patients. They found
that mDC1s isolated from either eosinophilic or non-eosinophilic
NPs could skew naïve T cells toward Th1 and Th17 phenotypes,
but only DCs from eosinophilic NPs were able to skew naïve T cells
toward a Th2 phenotype.74 They also investigated the mechanism
of Th2 skewing by mDC1s from eosinophilic NPs. They found that
the frequency of mDC1s expressing either OX40 ligand (OX40L) or
programmed death ligand-1 (PD-L1) was signiﬁcantly increased in
eosinophilic NPs.74 Furthermore, they also found that blockade of
either OX40L or PD-L1 suppressed the skewing of Th cells to pro-
duce type 2 cytokines.74 TSLP-R is known to be highly expressed on
mDC1s and TSLP-stimulated mDCs induce naive CD4þ T cells to
differentiate intoTh2 cells.78 Importantly, this response is known to
be via OX40L and TSLP induces expression of OX40L on mDCs.78
This evidence indicates that mDC1s in eosinophilic NPs may be
primed by TSLP and thereafter control Th2 responses in NPs. Since
TSLP is known to strongly induce the production of chemokines,
TARC, MDC and eotaxins, in mDC,78 mDC1s in eosinophilic NPs may
also contribute to the recruitment of Th2 cells and eosinophils into
NPs.
Since epithelial cells are one of the main sources of TSLP, we
initially hypothesized that mDC1s might be accumulated in the
epithelium of NPs, yet we found that accumulation of mDC1s can be
detected in lamina propria but not in epithelium.83 However,
CD1cþ mDC1s were frequently found just below the surface of the
epithelium in NPs (Fig. 2F). This suggests that it may be easy for
mDC1s to interact with epithelial cells and epithelial cell derived
cytokines including TSLP in NPs. This evidence suggests that TSLP
A. Kato / Allergology International 64 (2015) 121e130126may control adaptive type 2 inﬂammation through activation of
mDCs and induction of Th2 differentiation (Fig. 1).
The mechanism of accumulation of mDCs in eosinophilic NPs is
not clear. We recently reported that the chemokines CCL18 and
CCL23 were signiﬁcantly elevated in NPs.86,87 CCL23 is known to
recruit mDCs via the receptor CCR1.88 We also found that levels of
CCL23 signiﬁcantly correlated with CCR1 and CD1c in NP tissues.87
CCL18 is known to be chemotactic for immature mDC1.89 These
results suggest that overproduction of CCL18 and CCL23 may
contribute to the accumulation of mDC1 in NPs. CCL18 is also
known to recruit Th2 cells via CCR8.90 Interestingly, we also iden-
tiﬁed that CCL18 and CCL23 were mainly produced by M2 macro-
phages and eosinophils, respectively.86,87 CCL23 also potently
recruits CCR1þ monocytes and macrophages.88 Since eosinophilic
NPs are in a type 2 microenvironment, recruited macrophages can
be differentiated into the M2 phenotype by type 2 cytokines.
CD163þ M2 macrophages are known to be accumulated in NPs
(Fig. 2E).19,87,91 They are known to produce eosinophil chemokines
including eotaxins and MCP-4.92 This data indicates that produc-
tion of CCL23 from eosinophils, recruitment of macrophages, dif-
ferentiation into M2 macrophages and production of eosinophil
chemokines from M2 macrophages may constitute a positive
feedback loop to amplify the eosinophilia in NPs (Fig. 1).
Mast cells
Mast cells play key roles in host defense, homeostasis, tissue
repair, andmechanisms of allergic inﬂammation. Mast cells express
the high-afﬁnity IgE receptor, FcεRI. Upon cross-linking of the FcεRI
via IgE-antigen, mast cells release several pre-stored mediators,
including histamine and proteases and synthesize many mediators
including prostaglandins (PGs), cysteinyl leukotrienes (CysLTs) and
type 2 cytokines especially IL-5 and IL-13. Recent reports suggest
that a subset of patients with asthma and eosinophilic esophagitis
that displayed a type 2 cytokine high-phenotype have elevated
mast cells.93e96 Interestingly, mast cells primary accumulated in
the epithelium.93,94 In addition, intraepithelial mast cells in these
patients showed a mast cell-tryptase (MC-T) but not mast cell-
tryptase/chymase (MC-TC) phenotype.95,96 In the case of CRS, our
group found that mast cells were signiﬁcantly elevated in mucosal
and glandular epithelium but not within the lamina propria in NPs
(Fig. 2D).48 Interestingly, mast cell phenotypes were different in
mucosal and glandular epithelium. Takabayashi et al. found that
mucosal epithelial mast cells showed an MC-T phenotype. In
contrast, glandular epithelial mast cells showed an MC-TC pheno-
types in the US.48 Cao et al. also found signiﬁcant elevation of MC-T
in the mucosal epithelium of eosinophilic NPs in China.97 These
results suggest that mast cells are highly elevated in the epithelium
of eosinophilic CRSwNP across the world. However, functional
differences between MC-T and MC-TC in the pathogenesis of CRS
will need to be further investigated.
Mast cells are known to express IL-1R, IL-33R (ST2) and TSLP-R
on the cell surface and to respond to these ligands. Although TSLP
alone isn't sufﬁcient to stimulate mast cells, TSLP synergizes with
IL-1 and IL-33; potently activating mast cells to produce type 2
cytokines.98,99 As described, mast cell numbers were increased only
within the NP epithelium in patients with eosinophilic CRSwNP.48
However, the speciﬁc role of the epithelium in the direct activa-
tion of mast cells was not clear. We hypothesized that epithelial
cells can produce a combination of cytokines that directly activates
intraepithelial mast cells to produce type 2 cytokines. We therefore
investigated the effect of viruses, TLR ligands and cytokines on the
interaction of mast cells and epithelial cells in vitro. We found that
airway epithelial cells directly promoted production of type 2 cy-
tokines in mast cells during viral infection through the productionof IL-1 and TSLP and that this occurred only in a type 2 microen-
vironment.99 We initially expected that IL-33 released from
epithelial cells contributes to this reaction. However, we could not
detect IL-33 protein in poly(I:C) stimulated or inﬂuenza infected
epithelial cells and ST2-Fc fusion protein could not block this
response.99 This suggests that intraepithelial mast cells in eosino-
philic NPs may contribute to the production of type 2 cytokines via
interaction with epithelial cytokines TSLP and IL-1 in response to
pathogens on epithelial cells. Interestingly, Iikura et al. found that
IL-1 and IL-33 enhanced IgE receptor mediated type 2 cytokine
production in mast cells.100 Since mast cells produce type 2 cyto-
kines through epithelial-derived cytokines and IgE-mediated re-
actions, mast cells may contribute to both innate and adaptive type
2 inﬂammation in eosinophilic NPs (Fig. 1).
ILC2
The last population of type 2 cytokine producing cells to discuss
is innate lymphoid cells (ILCs). ILCs are a recently identiﬁed minor
population of immune cells that lack antigen receptors and lineage
(Lin) markers. ILCs are activated by innate immune signaling
including pathogens and innate cytokines. Like T helper cells, ILCs
can be classiﬁed into 3 subsets, ILC1, ILC2 and ILC3 dependent on
the production of cytokines.101,102 Among them, ILC2s produce
large quantities of type 2 cytokines (including IL-5 and IL-13). The
ﬁrst evidence for ILC2-like cells was reported by Fort et al. in
2001.103 An ILC2 population was identiﬁed by several groups in
2010 in mice and variously named nuocytes, natural helper cells,
innate helper 2 cells and others.104e106 In 2013, Spits et al. orga-
nized the nomenclature of the ILC family members and deﬁned
group 2 ILCs (ILC2s) as ILCs that produce type 2 cytokines and are
dependent on GATA3 and RORa for their development and
function.101
Human ILC2s were discovered by Mj€osberg et al. in 2011 and
were deﬁned as CD45þ, Lin, CD127þ, CRTH2þ cells.107 Importantly,
they also identiﬁed an ILC2 population in NPs of Dutch patients and
found that ILC2s were signiﬁcantly elevated in NPs compared to
control sinus mucosa.107 Several groups have now conﬁrmed the
elevation of ILC2 in NPs in the US and Australia.58,61,108 However, in
my knowledge, the presence of ILC2s in eosinophilic NPs in the
Asian population has yet not been investigated. Future study is
required to identify ILC2s in the Asian population and investigate
whether ILC2s are signiﬁcantly elevated in eosinophilic NPs
compared to non-eosinophilic NPs and control sinus mucosa.
ILC2s are known to express IL-33R and TSLP-R on the cell sur-
face. IL-33 and TSLP are known to induce type 2 cytokine produc-
tion in ILC2s, although the effect by individual cytokines is minimal.
However, the combination of TSLP and IL-33 synergistically en-
hances the production of type 2 cytokines including IL-5 and IL-13
in human ILC2s isolated from peripheral blood and NPs.109,110 As
described above, TSLP is signiﬁcantly upregulated in eosinophilic
NPs.7,71 IL-33 is present but not elevated in NPs.61,62 This suggests
that ILC2smay contribute to the local innate type 2 inﬂammation in
eosinophilic NPs by responding to TSLP and IL-33 with the pro-
duction of type 2 cytokines.
CRTH2 is now known to be one of the key markers of human
ILC2. CRTH2 is a chemokine receptor homologous molecule and is
known as the PGD2 receptor 2 (DP2). PGD2 is known to recruit Th2,
eosinophils and basophils via CRTH2.111 Chang et al. recently
discovered that PGD2 also induced chemotaxis of human ILC2s.112
Xue et al. found that PGD2 dependent migration of ILC2 was via
CRTH2.113 Importantly, Xue et al. also found that PGD2 strongly
induced the production of type 2 cytokines including IL-4, IL-5 and
IL-13 in ILC2s via the activation of CRTH2.113 Mast cells are the one
of the major sources of PGD2. Xue et al. also looked at the role of
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pernatants of degranulated mast cells induced ILC2 migration and
production of type 2 cytokines in ILC2.113 Mast cells also produce
other pro allergic arachidonic acid metabolites called CysLTs
including LTC4 upon degranulation.114 Doherty et al. found that
CysLTR1 was expressed on ILC2s, and LTC4 and LTD4 strongly
induced the production of type 2 cytokines in ILC2s.115 Since mast
cells are highly accumulated and many of them are activated and
degranulated in eosinophilic NPs,48,97 degranulation of mast cells
may further enhance the recruitment of ILC2s and the production of
type 2 cytokines in ILC2s via release of PGD2 and LTC4/D4 from
mast cells and activation of CRTH2 and CysLTR1 on ILC2s in
eosinophilic NPs (Fig. 1).
B-lineage cells
We have described immune cells that produce type 2 cytokines
and cells that control type 2 cytokine production in these cells. In
the last section, we will focus on the B-lineage cells that can be
activated by type 2 cytokines in eosinophilic NPs.
In general, B cell maturation and expansion occur in germinal
centers of the lymphoid organs. However, there are compelling
reasons to believe that local proliferation and activation of B-
lineage cells, B cells, plasmablasts and plasma cells, are of central
pathogenic importance in several airway inﬂammatory dis-
eases.116 The production of IgA and IgE from B-lineage cells is
known to be critical to allergic disease via the activation of
airway eosinophils and mast cells, respectively, in response to
antigen exposure.116 Several groups have shown that extensive
class switch recombination and antigen speciﬁc IgA and IgE
production can occur in the nasal and bronchial mucosa as part of
inﬂammatory diseases such as allergic rhinitis and asthma.117e120
Due to the recognized importance of IgA and IgE in the airway,
the local activation of B-lineage cells in the airway has been
proposed to be an important event in the pathogenesis of allergic
airway diseases.
In the case of CRS, B cell accumulation can be found in the
lamina propria of NPs (Fig. 2H). Van Zele et al. found that CD20þ B
cells and CD138þ plasma cells are elevated in NPs by immunohis-
tochemistry.6 Several groups also found B cell clusters and B cell
follicle-like structures in NPs.121e124 However, unlike the germinal
center, the structure of these local follicles was not well organized
(Fig. 2I). In addition, we also found B cell clusters and follicles in the
nasal mucosa of CRSsNP and control subjects and found that they
were not elevated in NPs.125 The role of B cell clusters and follicles
in nasal mucosa needs further investigation. Our group also char-
acterized B-lineage cells in CRS by ﬂow cytometry and found that B-
lineage cells, B cells, plasmablasts and plasma cells, were all
elevated in NPs compared to uncinate process tissues from control
subjects and patients with CRSsNP.125
In addition to accumulation of B-lineage cells in NPs, many
groups reported the elevation of IgE in NPs. Gevaert P et al. found
that total IgE, Staphylococcus aureus enterotoxin-speciﬁc IgE and
IgE positive cells were elevated in NPs.121,123 Our group also eval-
uated the immunoglobulin isotypes, IgM, IgG, IgA and IgE in the
nasal mucosa of CRS and found that all isotypes (except IgG3) were
signiﬁcantly elevated in NPs.125 In contrast, we could not ﬁnd the
elevation of immunoglobulin isotypes, except IgE, in serum of pa-
tients with CRSwNP. In addition, we found that only less than 10% of
the antibodies found in NP tissues can be attributed to vascular
leak.125 These results indicate that the antibodies found in NP tis-
sues were produced locally. Moreover, several groups found the
elevation of ε-germline gene transcripts suggesting that IgE class
switch recombination can occur in NPs.123 Interestingly, Cao et al.
and Baba et al. reported that local IgE production and IgE classswitch recombination were found only in eosinophilic NPs but not
in non-eosinophilic NPs in China and Japan.97,124
Several factors are involved in B-lineage cell responses.116 As
described above, type 2 cytokine IL-13 is known to be elevated in
eosinophilic NPs. IL-13 is a critical inducer of IgE class switch
recombination and IgE production in B cells.116We also found that B
cell-activation factor of the TNF family (BAFF) was signiﬁcantly
elevated in NP tissues and nasal lavage from patients with
CRSwNP.126 Gevaert et al. conﬁrmed elevation of BAFF in NPs in
Belgium.123 BAFF is an essential factor for B cell maturation and
survival. BAFF also induces T cell-dependent and independent
immunoglobulin class switching and production.65,116 Importantly,
expression of BAFF positively correlated with B cell marker CD20
and one of the BAFF receptors, TACI, in sinus mucosa suggesting
that BAFF may be a key B cell activation factor in NPs.126 Since BAFF
cannot induce migration of B-lineage cells, we also looked at che-
mokines and found elevation of the B cell chemokine CXCL12 (SDF-
1) and CXCL13 (BCL) in NPs.122 This data indicates that chemokines
CXCL12 and CXCL13 may contribute to the initial recruitment of B-
lineage cells, BAFF may be involved in the proliferation and acti-
vation of B-lineage cells and IL-13 is a key factor for the local pro-
duction of IgE in NPs.
IgE induces allergic inﬂammation by activation of mast cells and
basophils and plays an important role in allergic diseases including
asthma. Omalizumab, which is a humanized anti-human IgE
monoclonal antibody, is approved and known to be effective in the
treatment of patients with severe allergic asthma.127 As described
above, mast cells and IgE are highly elevated in eosinophilic NPs.
We also found that basophils were elevated in NPs in the US.128
Gevaert et al. performed clinical trials of anti-IgE in patients with
CRSwNP who were comorbid with asthma. They found that Oma-
lizumab showed signiﬁcant reduction in NP score and had a
beneﬁcial effect on QOL scores.129 This suggests that IgE can be an
important therapeutic target for patients with eosinophilic NPs.
As mentioned above, the cytokine BAFF is elevated in NPs. BAFF
is now known as a pathogenic factor for autoimmune dis-
eases.130e132 More importantly anti-BAFF (Belimumab) has very
recently been approved for the treatment of lupus.133 We therefore
looked at the presence of autoantibodies in CRS. We found that
anti-dsDNA antibody and anti-BP-180 antibody were signiﬁcantly
elevated in NPs.134,135 Since we could not ﬁnd elevation of auto-
antibodies in the serum of polypoid patients, this should be a local
phenomenon. Interestingly we found that anti-dsDNA antibodies
were more elevated in NPs who had revision surgery.135 This in-
dicates that autoantibodies may be a pathogenic factor and/or
biomarker of severe NPs. Further study will be required to identify
the pathogenic role of autoantibodies in NPs.
Conclusions
This review primary focused on immune cells and cytokines
that control initiation and ampliﬁcation of inﬂammation in CRS.
Although CRSsNP is known to be characterized by type 1 inﬂam-
mation with elevated levels of IFN-g, CRSsNP is a heterogeneous
disease and sub-classiﬁcation of this disease and further investi-
gation of the inﬂammatory patterns in each group might be
required in the future. Although the majority of CRSwNP cases in
western countries show type 2 inﬂammation and eosinophilia,
about 50% of CRSwNP in Asian countries show a non-eosinophilic
phenotype. However, the prevalence of eosinophilic NPs has
increased in Asia in the past 10e20 years and may continue to
increase in the future. Inﬂammation in eosinophilic CRSwNP is
controlled by type 2 cytokines including IL-5 and IL-13 that can be
produced from Th2, mast cells and ILC2 in eosinophilic NP.
Epithelial cytokines including TSLP might control production of
A. Kato / Allergology International 64 (2015) 121e130128type 2 cytokines in these cell types. Recent clinical trials showed
the beneﬁcial effect on eosinophilic NPs and/or asthma by
monoclonal antibodies against IL-5, IL-4Ra, IgE and TSLP sug-
gesting that they can be novel therapeutic targets for eosinophilic
CRSwNP.
Acknowledgments
This research was supported in part by NIH grants, R01
AI104733, R21 HL113913, U19 AI106683 and R37 HL068546 and by
a grant from the Ernest S. Bazley Trust.
The author acknowledges Ms. Julie Poposki for proofreading of
this review. The author extends my gratitude to Ms. Jacqueline
Schaffer for her input and guidance in preparation of the illustra-
tion in this review.
Conﬂict of interest
The author has no conﬂict of interest to declare.
References
1. Bhattacharyya N. Incremental health care utilization and expenditures for
chronic rhinosinusitis in the United States. Ann Otol Rhinol Laryngol 2011;120:
423e7.
2. Meltzer EO, Hamilos DL, Hadley JA, Lanza DC, Marple BF, Nicklas RA, et al.
Rhinosinusitis: establishing deﬁnitions for clinical research and patient care.
J Allergy Clin Immunol 2004;114:155e212.
3. Kern RC, Conley DB, Walsh W, Chandra R, Kato A, Tripathi-Peters A, et al.
Perspectives on the etiology of chronic rhinosinusitis: an immune barrier
hypothesis. Am J Rhinol 2008;22:549e59.
4. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. European
position paper on rhinosinusitis and nasal polyps 2012. Rhinol Suppl 2012:
1e298. 3 p preceding table of contents.
5. Bachert C, Van Bruaene N, Toskala E, Zhang N, Olze H, Scadding G, et al.
Important research questions in allergy and related diseases: 3-chronic rhi-
nosinusitis and nasal polyposis e a GALEN study. Allergy 2009;64:520e33.
6. Van Zele T, Claeys S, Gevaert P, Van Maele G, Holtappels G, Van
Cauwenberge P, et al. Differentiation of chronic sinus diseases by measure-
ment of inﬂammatory mediators. Allergy 2006;61:1280e9.
7. Nagarkar DR, Poposki JA, Tan BK, Comeau MR, Peters AT, Hulse KE, et al.
Thymic stromal lymphopoietin activity is increased in nasal polyps of patients
with chronic rhinosinusitis. J Allergy Clin Immunol 2013;132:593e600. e12.
8. Van Bruaene N, Derycke L, Perez-Novo CA, Gevaert P, Holtappels G, De
Ruyck N, et al. TGF-beta signaling and collagen deposition in chronic rhino-
sinusitis. J Allergy Clin Immunol 2009;124:253e9. 9.e1e2.
9. Li X, Meng J, Qiao X, Liu Y, Liu F, Zhang N, et al. Expression of TGF, matrix
metalloproteinases, and tissue inhibitors in Chinese chronic rhinosinusitis.
J Allergy Clin Immunol 2010;125:1061e8.
10. Shi LL, Xiong P, Zhang L, Cao PP, Liao B, Lu X, et al. Features of airway
remodeling in different types of Chinese chronic rhinosinusitis are associated
with inﬂammation patterns. Allergy 2013;68:101e9.
11. Takabayashi T, Kato A, Peters AT, Hulse KE, Suh LA, Carter R, et al. Excessive
ﬁbrin deposition in nasal polyps caused by ﬁbrinolytic impairment through
reduction of tissue plasminogen activator expression. Am J Respir Crit Care
Med 2013;187:49e57.
12. Van Bruaene N, Bachert C. Tissue remodeling in chronic rhinosinusitis. Curr
Opin Allergy Clin Immunol 2011;11:8e11.
13. Yang YC, Zhang N, Van Crombruggen K, Hu GH, Hong SL, Bachert C. Trans-
forming growth factor-beta1 in inﬂammatory airway disease: a key for un-
derstanding inﬂammation and remodeling. Allergy 2012;67:1193e202.
14. Chen Q, Jin M, Yang F, Zhu J, Xiao Q, Zhang L. Matrix metalloproteinases:
inﬂammatory regulators of cell behaviors in vascular formation and remod-
eling. Mediat Inﬂamm 2013;2013:928315.
15. Watelet JB, Bachert C, Claeys C, Van Cauwenberge P. Matrix metal-
loproteinases MMP-7, MMP-9 and their tissue inhibitor TIMP-1: expression in
chronic sinusitis vs nasal polyposis. Allergy 2004;59:54e60.
16. Regateiro FS, Howie D, Cobbold SP, Waldmann H. TGF-beta in transplantation
tolerance. Curr Opin Immunol 2011;23:660e9.
17. Al-Alawi M, Hassan T, Chotirmall SH. Transforming growth factor beta and
severe asthma: a perfect storm. Respir Med 2014;108:1409e23.
18. Sejima T, Holtappels G, Kikuchi H, Imayoshi S, Ichimura K, Bachert C. Cytokine
proﬁles in Japanese patients with chronic rhinosinusitis. Allergol Int 2012;61:
115e22.
19. Takabayashi T, Kato A, Peters AT, Hulse KE, Suh LA, Carter R, et al. Increased
expression of factor XIII-A in patients with chronic rhinosinusitis with nasal
polyps. J Allergy Clin Immunol 2013;132:584e92. e4.
20. Del Rosso M, Fibbi G, Pucci M, Margheri F, Serrati S. The plasminogen acti-
vation system in inﬂammation. Front Biosci 2008;13:4667e86.21. Bagoly Z, Katona E, Muszbek L. Factor XIII and inﬂammatory cells. Thromb Res
2012;129(Suppl. 2):S77e81.
22. Muszbek L, Bereczky Z, Bagoly Z, Komaromi I, Katona E. Factor XIII: a coag-
ulation factor with multiple plasmatic and cellular functions. Physiol Rev
2011;91:931e72.
23. Van Bruaene N, Perez-Novo CA, Basinski TM, Van Zele T, Holtappels G, De
Ruyck N, et al. T-cell regulation in chronic paranasal sinus disease. J Allergy
Clin Immunol 2008;121:1435e41. 41e1e3.
24. Cao PP, Li HB, Wang BF, Wang SB, You XJ, Cui YH, et al. Distinct immuno-
pathologic characteristics of various types of chronic rhinosinusitis in adult
Chinese. J Allergy Clin Immunol 2009;124:478e84. 84e1e2.
25. Park SJ, Kim TH, Jun YJ, Lee SH, Ryu HY, Jung KJ, et al. Chronic rhinosinusitis
with polyps and without polyps is associated with increased expression of
suppressors of cytokine signaling 1 and 3. J Allergy Clin Immunol 2013;131:
772e80.
26. Zhang Q, Wang CS, Han DM, Sy C, Huang Q, Sun Y, et al. Differential
expression of Toll-like receptor pathway genes in chronic rhinosinusitis with
or without nasal polyps. Acta Otolaryngol 2013;133:165e73.
27. Hamilos DL, Leung DY, Wood R, Bean DK, Song YL, Schotman E, et al. Eosin-
ophil inﬁltration in nonallergic chronic hyperplastic sinusitis with nasal pol-
yposis (CHS/NP) is associated with endothelial VCAM-1 upregulation and
expression of TNF-alpha. Am J Respir Cell Mol Biol 1996;15:443e50.
28. Jankowski R, Bouchoua F, Cofﬁnet L, Vignaud JM. Clinical factors inﬂuencing
the eosinophil inﬁltration of nasal polyps. Rhinology 2002;40:173e8.
29. Claeys S, Van Hoecke H, Holtappels G, Gevaert P, De Belder T, Verhasselt B,
et al. Nasal polyps in patients with and without cystic ﬁbrosis: a differentia-
tion by innate markers and inﬂammatory mediators. Clin Exp Allergy 2005;35:
467e72.
30. Polzehl D, Moeller P, Riechelmann H, Perner S. Distinct features of chronic
rhinosinusitis with and without nasal polyps. Allergy 2006;61:1275e9.
31. Zhang N, Van Zele T, Perez-Novo C, Van Bruaene N, Holtappels G, DeRuyck N,
et al. Different types of T-effector cells orchestrate mucosal inﬂammation in
chronic sinus disease. J Allergy Clin Immunol 2008;122:961e8.
32. Payne SC, Borish L, Steinke JW. Genetics and phenotyping in chronic sinusitis.
J Allergy Clin Immunol 2011;128:710e20. quiz 21e2.
33. Ikeda K, Shiozawa A, Ono N, Kusunoki T, Hirotsu M, Homma H, et al. Sub-
classiﬁcation of chronic rhinosinusitis with nasal polyp based on eosinophil
and neutrophil. Laryngoscope 2013;123:E1e9.
34. Kim JW, Hong SL, Kim YK, Lee CH, Min YG, Rhee CS. Histological and
immunological features of non-eosinophilic nasal polyps. Otolaryngol Head
Neck Surg 2007;137:925e30.
35. Yoshimura K, Kawata R, Haruna S, Moriyama H, Hirakawa K, Fujieda S, et al.
Clinical epidemiological study of 553 patients with chronic rhinosinusitis in
Japan. Allergol Int 2011;60:491e6.
36. Wen W, Liu W, Zhang L, Bai J, Fan Y, Xia W, et al. Increased neutrophilia in
nasal polyps reduces the response to oral corticosteroid therapy. J Allergy Clin
Immunol 2012;129:1522e8. e5.
37. Kim SJ, Lee KH, Kim SW, Cho JS, Park YK, Shin SY. Changes in histological
features of nasal polyps in a Korean population over a 17-year period. Oto-
laryngol Head Neck Surg 2013;149:431e7.
38. Katotomichelakis M, Tantilipikorn P, Holtappels G, De Ruyck N, Feng L, Van
Zele T, et al. Inﬂammatory patterns in upper airway disease in the same
geographical area may change over time. Am J Rhinol Allergy 2013;27:354e60.
39. Hamilos DL, Leung DY, Wood R, Cunningham L, Bean DK, Yasruel Z, et al.
Evidence for distinct cytokine expression in allergic versus nonallergic
chronic sinusitis. J Allergy Clin Immunol 1995;96:537e44.
40. Simon HU, Youseﬁ S, Schranz C, Schapowal A, Bachert C, Blaser K. Direct
demonstration of delayed eosinophil apoptosis as a mechanism causing tissue
eosinophilia. J Immunol 1997;158:3902e8.
41. Gevaert P, Lang-Loidolt D, Lackner A, Stammberger H, Staudinger H, Van
Zele T, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in
patients with nasal polyps. J Allergy Clin Immunol 2006;118:1133e41.
42. Gevaert P, Van Bruaene N, Cattaert T, Van Steen K, Van Zele T, Acke F, et al.
Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe
nasal polyposis. J Allergy Clin Immunol 2011;128:989e95. e1e8.
43. Beck LA, Stellato C, Beall LD, Schall TJ, Leopold D, Bickel CA, et al. Detection of
the chemokine RANTES and endothelial adhesion molecules in nasal polyps.
J Allergy Clin Immunol 1996;98:766e80.
44. Uguccioni M, Loetscher P, Forssmann U, Dewald B, Li H, Lima SH, et al.
Monocyte chemotactic protein 4 (MCP-4), a novel structural and functional
analogue of MCP-3 and eotaxin. J Exp Med 1996;183:2379e84.
45. Jahnsen FL, Haye R, Gran E, Brandtzaeg P, Johansen FE. Glucocorticosteroids
inhibit mRNA expression for eotaxin, eotaxin-2, and monocyte-chemotactic
protein-4 in human airway inﬂammation with eosinophilia. J Immunol
1999;163:1545e51.
46. Ponath PD, Qin S, Ringler DJ, Clark-Lewis I, Wang J, Kassam N, et al. Cloning of
the human eosinophil chemoattractant, eotaxin. Expression, receptor binding,
and functional properties suggest a mechanism for the selective recruitment
of eosinophils. J Clin Invest 1996;97:604e12.
47. Olze H, Forster U, Zuberbier T, Morawietz L, Luger EO. Eosinophilic nasal
polyps are a rich source of eotaxin, eotaxin-2 and eotaxin-3. Rhinology
2006;44:145e50.
48. Takabayashi T, Kato A, Peters AT, Suh LA, Carter R, Norton J, et al. Glandular
mast cells with distinct phenotype are highly elevated in chronic rhinosinu-
sitis with nasal polyps. J Allergy Clin Immunol 2012;130:410e20. e5.
A. Kato / Allergology International 64 (2015) 121e130 12949. Yao T, Kojima Y, Koyanagi A, Yokoi H, Saito T, Kawano K, et al. Eotaxin-1,
-2, and -3 immunoreactivity and protein concentration in the nasal polyps
of eosinophilic chronic rhinosinusitis patients. Laryngoscope 2009;119:
1053e9.
50. Licona-Limon P, Kim LK, Palm NW, Flavell RA. TH2, allergy and group 2 innate
lymphoid cells. Nat Immunol 2013;14:536e42.
51. Ziegler SF. Thymic stromal lymphopoietin and allergic disease. J Allergy Clin
Immunol 2012;130:845e52.
52. Comeau MR, Ziegler SF. The inﬂuence of TSLP on the allergic response.
Mucosal Immunol 2010;3:138e47.
53. Cayrol C, Girard JP. IL-33: an alarmin cytokine with crucial roles in innate
immunity, inﬂammation and allergy. Curr Opin Immunol 2014;31C:31e7.
54. Kondo Y, Yoshimoto T, Yasuda K, Futatsugi-Yumikura S, Morimoto M,
Hayashi N, et al. Administration of IL-33 induces airway hyperresponsiveness
and goblet cell hyperplasia in the lungs in the absence of adaptive immune
system. Int Immunol 2008;20:791e800.
55. Hurst SD, Muchamuel T, Gorman DM, Gilbert JM, Clifford T, Kwan S, et al. New
IL-17 family members promote Th1 or Th2 responses in the lung: in vivo
function of the novel cytokine IL-25. J Immunol 2002;169:443e53.
56. Bulek K, Swaidani S, Aronica M, Li X. Epithelium: the interplay between innate
and Th2 immunity. Immunol Cell Biol 2010;88:257e68.
57. Lam M, Hull L, McLachlan R, Snidvongs K, Chin D, Pratt E, et al. Clinical
severity and epithelial endotypes in chronic rhinosinusitis. Int Forum Allergy
Rhinol 2013;3:121e8.
58. Miljkovic D, Bassiouni A, Cooksley C, Ou J, Hauben E, Wormald PJ, et al. As-
sociation between group 2 innate lymphoid cells enrichment, nasal polyps
and allergy in chronic rhinosinusitis. Allergy 2014;69:1154e61.
59. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-
33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related
protein ST2 and induces T helper type 2-associated cytokines. Immunity
2005;23:479e90.
60. Kouzaki H, Iijima K, Kobayashi T, O'Grady SM, Kita H. The danger signal,
extracellular ATP, is a sensor for an airborne allergen and triggers IL-33
release and innate Th2-type responses. J Immunol 2011;186:4375e87.
61. Shaw JL, Fakhri S, Citardi MJ, Porter PC, Corry DB, Kheradmand F, et al. IL-
33-responsive innate lymphoid cells are an important source of IL-13 in
chronic rhinosinusitis with nasal polyps. Am J Respir Crit Care Med
2013;188:432e9.
62. Baba S, Kondo K, Kanaya K, Suzukawa K, Ushio M, Urata S, et al. Expression of
IL-33 and its receptor ST2 in chronic rhinosinusitis with nasal polyps.
Laryngoscope 2014;124:E115e22.
63. Zhou B, Headley MB, Aye T, Tocker J, Comeau MR, Ziegler SF. Reversal of
thymic stromal lymphopoietin-induced airway inﬂammation through inhi-
bition of Th2 responses. J Immunol 2008;181:6557e62.
64. Jessup HK, Brewer AW, Omori M, Rickel EA, Budelsky AL, Yoon BR, et al. In-
tradermal administration of thymic stromal lymphopoietin induces a T cell-
and eosinophil-dependent systemic Th2 inﬂammatory response. J Immunol
2008;181:4311e9.
65. Kato A, Favoreto Jr S, Avila PC, Schleimer RP. TLR3- and Th2 cytokine-
dependent production of thymic stromal lymphopoietin in human airway
epithelial cells. J Immunol 2007;179:1080e7.
66. Kato A, Schleimer RP. Beyond inﬂammation: airway epithelial cells are at the
interface of innate and adaptive immunity. Curr Opin Immunol 2007;19:
711e20.
67. Allakhverdi Z, Comeau MR, Smith DE, Toy D, Endam LM, Desrosiers M, et al.
CD34þ hemopoietic progenitor cells are potent effectors of allergic inﬂam-
mation. J Allergy Clin Immunol 2009;123:472e8.
68. Liu T, Li TL, Zhao F, Xie C, Liu AM, Chen X, et al. Role of thymic stromal
lymphopoietin in the pathogenesis of nasal polyposis. Am J Med Sci 2011;341:
40e7.
69. Kimura S, Pawankar R, Mori S, Nonaka M, Masuno S, Yagi T, et al. Increased
expression and role of thymic stromal lymphopoietin in nasal polyposis. Al-
lergy Asthma Immunol Res 2011;3:186e93.
70. Ouyang Y, Fan E, Li Y, Wang X, Zhang L. Clinical characteristics and expression
of thymic stromal lymphopoetin in eosinophilic and non-eosinophilic chronic
rhinosinusitis. ORL J Otorhinolaryngol Relat Spec 2013;75:37e45.
71. Boita M, Garzaro M, Raimondo L, Riva G, Mazibrada J, Pecorari G, et al.
Eosinophilic inﬂammation of chronic rhinosinusitis with nasal polyps is
related to OX40 ligand expression. Innate Immun 2015;21:167e74.
72. Gauvreau GM, O'Byrne PM, Boulet LP, Wang Y, Cockcroft D, Bigler J, et al.
Effects of an anti-TSLP antibody on allergen-induced asthmatic responses.
N Engl J Med 2014;370:2102e10.
73. Derycke L, Eyerich S, Van Crombruggen K, Perez-Novo C, Holtappels G,
Deruyck N, et al. Mixed T helper cell signatures in chronic rhinosinusitis with
and without polyps. PLoS One 2014;9:e97581.
74. Shi LL, Song J, Xiong P, Cao PP, Liao B, Ma J, et al. Disease-speciﬁc T-helper
cell polarizing function of lesional dendritic cells in different types of
chronic rhinosinusitis with nasal polyps. Am J Respir Crit Care Med
2014;190:628e38.
75. Omori M, Ziegler S. Induction of IL-4 expression in CD4(þ) T cells by thymic
stromal lymphopoietin. J Immunol 2007;178:1396e404.
76. He R, Oyoshi MK, Garibyan L, Kumar L, Ziegler SF, Geha RS. TSLP acts on
inﬁltrating effector T cells to drive allergic skin inﬂammation. Proc Natl Acad
Sci U S A 2008;105:11875e80.77. Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, et al. Human
epithelial cells trigger dendritic cell mediated allergic inﬂammation by pro-
ducing TSLP. Nat Immunol 2002;3:673e80.
78. Ito T, Wang YH, Duramad O, Hori T, Delespesse GJ, Watanabe N, et al. TSLP-
activated dendritic cells induce an inﬂammatory T helper type 2 cell response
through OX40 ligand. J Exp Med 2005;202:1213e23.
79. Rochman I, Watanabe N, Arima K, Liu YJ, Leonard WJ. Cutting edge: direct
action of thymic stromal lymphopoietin on activated human CD4þ T cells.
J Immunol 2007;178:6720e4.
80. Lu N, Wang YH, Arima K, Hanabuchi S, Liu YJ. TSLP and IL-7 use two different
mechanisms to regulate human CD4þ T cell homeostasis. J Exp Med 2009;206:
2111e9.
81. Reefer AJ, Hulse KE, Lannigan JA, Solga MD, Wright PW, Kelly LA, et al. Flow
cytometry imaging identiﬁes rare T(H)2 cells expressing thymic stromal
lymphopoietin receptor in a proallergic milieu. J Allergy Clin Immunol
2010;126:1049e58. 58e1e10.
82. Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage:
ontogeny and function of dendritic cells and their subsets in the steady state
and the inﬂamed setting. Annu Rev Immunol 2013;31:563e604.
83. Poposki JA, Peterson A, Welch K, Schleimer RP, Hulse KE, Peters AT, et al.
Elevated presence of myeloid dendritic cells in nasal polyps of patients with
chronic rhinosinusitis. Clin Exp Allergy 2015;45:384e93.
84. Pezato R, Perez-Novo CA, Holtappels G, De Ruyck N, Van Crombruggen K,
De Vos G, et al. The expression of dendritic cell subsets in severe chronic
rhinosinusitis with nasal polyps is altered. Immunobiology 2014;219:
729e36.
85. Yerkovich ST, Roponen M, Smith ME, McKenna K, Bosco A, Subrata LS, et al.
Allergen-enhanced thrombomodulin (blood dendritic cell antigen 3, CD141)
expression on dendritic cells is associated with a TH2-skewed immune
response. J Allergy Clin Immunol 2009;123:209e16. e4.
86. Peterson S, Poposki JA, Nagarkar DR, Chustz RT, Peters AT, Suh LA, et al.
Increased expression of CC chemokine ligand 18 in patients with chronic
rhinosinusitis with nasal polyps. J Allergy Clin Immunol 2012;129:119e27.
e1e9.
87. Poposki JA, Uzzaman A, Nagarkar DR, Chustz RT, Peters AT, Suh LA, et al.
Increased expression of the chemokine CCL23 in eosinophilic chronic rhino-
sinusitis with nasal polyps. J Allergy Clin Immunol 2011;128:73e81. e4.
88. Nardelli B, Tiffany HL, Bong GW, Yourey PA, Morahan DK, Li Y, et al. Char-
acterization of the signal transduction pathway activated in human mono-
cytes and dendritic cells by MPIF-1, a speciﬁc ligand for CC chemokine
receptor 1. J Immunol 1999;162:435e44.
89. Vulcano M, Struyf S, Scapini P, Cassatella M, Bernasconi S, Bonecchi R, et al.
Unique regulation of CCL18 production by maturing dendritic cells. J Immunol
2003;170:3843e9.
90. Islam SA, Ling MF, Leung J, Shrefﬂer WG, Luster AD. Identiﬁcation of human
CCR8 as a CCL18 receptor. J Exp Med 2013;210:1889e98.
91. Krysko O, Holtappels G, Zhang N, Kubica M, Deswarte K, Derycke L, et al.
Alternatively activated macrophages and impaired phagocytosis of S. aureus
in chronic rhinosinusitis. Allergy 2011;66:396e403.
92. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional proﬁling of the
human monocyte-to-macrophage differentiation and polarization: new
molecules and patterns of gene expression. J Immunol 2006;177:7303e11.
93. Balzar S, Fajt ML, Comhair SA, Erzurum SC, Bleecker E, Busse WW, et al.
Mast cell phenotype, location, and activation in severe asthma. Data from
the Severe Asthma Research Program. Am J Respir Crit Care Med 2011;183:
299e309.
94. Hsu Blatman KS, Gonsalves N, Hirano I, Bryce PJ. Expression of mast cell-
associated genes is upregulated in adult eosinophilic esophagitis and re-
sponds to steroid or dietary therapy. J Allergy Clin Immunol 2011;127:
1307e8. e3.
95. Abonia JP, Blanchard C, Butz BB, Rainey HF, Collins MH, Stringer K, et al.
Involvement of mast cells in eosinophilic esophagitis. J Allergy Clin Immunol
2010;126:140e9.
96. Dougherty RH, Sidhu SS, Raman K, Solon M, Solberg OD, Caughey GH, et al.
Accumulation of intraepithelial mast cells with a unique protease phenotype
in T(H)2-high asthma. J Allergy Clin Immunol 2010;125:1046e53. e8.
97. Cao PP, Zhang YN, Liao B, Ma J, Wang BF, Wang H, et al. Increased local IgE
production induced by common aeroallergens and phenotypic alteration of
mast cells in Chinese eosinophilic, but not non-eosinophilic, chronic rhino-
sinusitis with nasal polyps. Clin Exp Allergy 2014;44:690e700.
98. Allakhverdi Z, Comeau MR, Jessup HK, Yoon BR, Brewer A, Chartier S, et al.
Thymic stromal lymphopoietin is released by human epithelial cells in
response to microbes, trauma, or inﬂammation and potently activates mast
cells. J Exp Med 2007;204:253e8.
99. Nagarkar DR, Poposki JA, Comeau MR, Biyasheva A, Avila PC, Schleimer RP,
et al. Airway epithelial cells activate TH2 cytokine production in mast cells
through IL-1 and thymic stromal lymphopoietin. J Allergy Clin Immunol
2012;130:225e32. e4.
100. Iikura M, Suto H, Kajiwara N, Oboki K, Ohno T, Okayama Y, et al. IL-33 can
promote survival, adhesion and cytokine production in human mast cells. Lab
Invest 2007;87:971e8.
101. Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. Innate
lymphoid cellsea proposal for uniform nomenclature. Nat Rev Immunol
2013;13:145e9.
A. Kato / Allergology International 64 (2015) 121e130130102. Sonnenberg GF, Mjosberg J, Spits H, Artis D. SnapShot: innate lymphoid cells.
Immunity 2013;39:622. e1.
103. Fort MM, Cheung J, Yen D, Li J, Zurawski SM, Lo S, et al. IL-25 induces IL-4, IL-5,
and IL-13 and Th2-associated pathologies in vivo. Immunity 2001;15:985e95.
104. Moro K, Yamada T, Tanabe M, Takeuchi T, Ikawa T, Kawamoto H, et al. Innate
production of T(H)2 cytokines by adipose tissue-associated c-Kit(þ)Sca-1(þ)
lymphoid cells. Nature 2010;463:540e4.
105. Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK, et al. Nuocytes
represent a new innate effector leukocyte that mediates type-2 immunity.
Nature 2010;464:1367e70.
106. Price AE, Liang HE, Sullivan BM, Reinhardt RL, Eisley CJ, Erle DJ, et al. Sys-
temically dispersed innate IL-13-expressing cells in type 2 immunity. Proc
Natl Acad Sci U S A 2010;107:11489e94.
107. Mjosberg JM, Trifari S, Crellin NK, Peters CP, van Drunen CM, Piet B, et al.
Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are deﬁned
by expression of CRTH2 and CD161. Nat Immunol 2011;12:1055e62.
108. Walford HH, Lund SJ, Baum RE, White AA, Bergeron CM, Husseman J, et al.
Increased ILC2s in the eosinophilic nasal polyp endotype are associated with
corticosteroid responsiveness. Clin Immunol 2014;155:126e35.
109. Mjosberg J, Bernink J, Golebski K, Karrich JJ, Peters CP, Blom B, et al. The
transcription factor GATA3 is essential for the function of human type 2
innate lymphoid cells. Immunity 2012;37:649e59.
110. Bartemes KR, Kephart GM, Fox SJ, Kita H. Enhanced innate type 2 immune
response in peripheral blood from patients with asthma. J Allergy Clin
Immunol 2014;134:671e8. e4.
111. Townley RG, Agrawal S. CRTH2 antagonists in the treatment of allergic re-
sponses involving TH2 cells, basophils, and eosinophils. Ann Allergy Asthma
Immunol 2012;109:365e74.
112. Chang JE, Doherty TA, Baum R, Broide D. Prostaglandin D2 regulates human
type 2 innate lymphoid cell chemotaxis. J Allergy Clin Immunol 2014;133:
899e901. e3.
113. Xue L, Salimi M, Panse I, Mjosberg JM, McKenzie AN, Spits H, et al. Prosta-
glandin D2 activates group 2 innate lymphoid cells through chemoattractant
receptor-homologous molecule expressed on TH2 cells. J Allergy Clin Immunol
2014;133:1184e94.
114. Kato A, Chustz RT, Ogasawara T, Kulka M, Saito H, Schleimer RP, et al.
Dexamethasone and FK506 inhibit expression of distinct subsets of chemo-
kines in human mast cells. J Immunol 2009;182:7233e43.
115. Doherty TA, Khorram N, Lund S, Mehta AK, Croft M, Broide DH. Lung type
2 innate lymphoid cells express cysteinyl leukotriene receptor 1, which
regulates TH2 cytokine production. J Allergy Clin Immunol 2013;132:
205e13.
116. Kato A, Hulse KE, Tan BK, Schleimer RP. B-lymphocyte lineage cells and the
respiratory system. J Allergy Clin Immunol 2013;131:933e57. quiz 58.
117. Pawankar R, Okuda M, Yssel H, Okumura K, Ra C. Nasal mast cells in perennial
allergic rhinitics exhibit increased expression of the Fc epsilonRI, CD40L, IL-4,
and IL-13, and can induce IgE synthesis in B cells. J Clin Invest 1997;99:
1492e9.
118. Takhar P, Smurthwaite L, Coker HA, Fear DJ, Banﬁeld GK, Carr VA, et al.
Allergen drives class switching to IgE in the nasal mucosa in allergic rhinitis.
J Immunol 2005;174:5024e32.119. Fiset PO, Cameron L, Hamid Q. Local isotype switching to IgE in airway mu-
cosa. J Allergy Clin Immunol 2005;116:233e6.
120. Takhar P, Corrigan CJ, Smurthwaite L, O'Connor BJ, Durham SR, Lee TH, et al.
Class switch recombination to IgE in the bronchial mucosa of atopic and
nonatopic patients with asthma. J Allergy Clin Immunol 2007;119:213e8.
121. Gevaert P, Holtappels G, Johansson SG, Cuvelier C, Cauwenberge P, Bachert C.
Organization of secondary lymphoid tissue and local IgE formation to
Staphylococcus aureus enterotoxins in nasal polyp tissue. Allergy 2005;60:
71e9.
122. Patadia M, Dixon J, Conley D, Chandra R, Peters A, Suh LA, et al. Evaluation of
the presence of B-cell attractant chemokines in chronic rhinosinusitis. Am J
Rhinol Allergy 2010;24:11e6.
123. Gevaert P, Nouri-Aria KT, Wu H, Harper CE, Takhar P, Fear DJ, et al. Local
receptor revision and class switching to IgE in chronic rhinosinusitis with
nasal polyps. Allergy 2013;68:55e63.
124. Baba S, Kondo K, Toma-Hirano M, Kanaya K, Suzukawa K, Ushio M, et al. Local
increase in IgE and class switch recombination to IgE in nasal polyps in
chronic rhinosinusitis. Clin Exp Allergy 2014;44:701e12.
125. Hulse KE, Norton JE, Suh L, Zhong Q, Mahdavinia M, Simon P, et al. Chronic
rhinosinusitis with nasal polyps is characterized by B-cell inﬂammation and
EBV-induced protein 2 expression. J Allergy Clin Immunol 2013;131:1075e83.
83 e1e7.
126. KatoA, PetersA, Suh L, Carter R,Harris KE, ChandraR, et al. Evidenceof a role for B
cell-activating factor of the TNF family in the pathogenesis of chronic rhinosi-
nusitis with nasal polyps. J Allergy Clin Immunol 2008;121:1385e92. 92 e1e2.
127. McKeage K. Omalizumab: a review of its use in patients with severe persistent
allergic asthma. Drugs 2013;73:1197e212.
128. Mahdavinia M, Carter RG, Ocampo CJ, Stevens W, Kato A, Tan BK, et al. Ba-
sophils are elevated in nasal polyps of patients with chronic rhinosinusitis
without aspirin sensitivity. J Allergy Clin Immunol 2014;133:1759e63.
129. Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, et al.
Omalizumab is effective in allergic and nonallergic patients with nasal polyps
and asthma. J Allergy Clin Immunol 2013;131:110e6. e1.
130. Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, Fessler BJ, et al. Cutting
edge: a role for B lymphocyte stimulator in systemic lupus erythematosus.
J Immunol 2001;166:6e10.
131. Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, et al. The level of
BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's
syndrome. Ann Rheum Dis 2003;62:168e71.
132. Mackay F, Silveira PA, Brink R. B cells and the BAFF/APRIL axis: fast-forward
on autoimmunity and signaling. Curr Opin Immunol 2007;19:327e36.
133. Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al.
Efﬁcacy and safety of belimumab in patients with active systemic lupus er-
ythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet
2011;377:721e31.
134. Jeffe JS, Seshadri S, Hamill KJ, Huang JH, Carter R, Suh L, et al. A role for anti-
BP180 autoantibodies in chronic rhinosinusitis. Laryngoscope 2013;123:
2104e11.
135. Tan BK, Li QZ, Suh L, Kato A, Conley DB, Chandra RK, et al. Evidence for
intranasal antinuclear autoantibodies in patients with chronic rhinosinusitis
with nasal polyps. J Allergy Clin Immunol 2011;128:1198e206. e1.
